AngioDynamics, Inc. (ANGO) EPS Estimated At $0.16

June 20, 2017 - By Maria Brooks

 AngioDynamics, Inc. (ANGO) EPS Estimated At $0.16
Investors sentiment increased to 3.16 in 2016 Q4. Its up 0.55, from 2.61 in 2016Q3. It improved, as 8 investors sold AngioDynamics, Inc. shares while 23 reduced holdings. 32 funds opened positions while 66 raised stakes. 61.14 million shares or 119.62% more from 27.84 million shares in 2016Q3 were reported.
Blackrock Inv Limited Company reported 156,147 shares. Systematic Financial Lp holds 0.21% or 786,652 shares in its portfolio. Legal & General Gp Public Ltd Co holds 0% of its portfolio in AngioDynamics, Inc. (NASDAQ:ANGO) for 51,284 shares. Federated Investors Incorporated Pa reported 1,138 shares stake. Barclays Plc accumulated 48,560 shares or 0% of the stock. Renaissance Limited Com has invested 0.02% of its portfolio in AngioDynamics, Inc. (NASDAQ:ANGO). California Public Employees Retirement Systems holds 0.01% or 196,700 shares. Moreover, Bogle Inv Mngmt L P De has 0.25% invested in AngioDynamics, Inc. (NASDAQ:ANGO). Teachers Retirement Of The State Of Kentucky owns 4,000 shares. Prudential Finance has invested 0.01% of its portfolio in AngioDynamics, Inc. (NASDAQ:ANGO). Teton Advsrs reported 0.09% of its portfolio in AngioDynamics, Inc. (NASDAQ:ANGO). Sei Investments holds 0% or 185 shares in its portfolio. The New York-based State Bank Of New York Mellon Corp has invested 0% in AngioDynamics, Inc. (NASDAQ:ANGO). 175,371 were accumulated by Tiaa Cref Investment Management Limited Co. State Board Of Administration Of Florida Retirement has invested 0% in AngioDynamics, Inc. (NASDAQ:ANGO).

Investors wait AngioDynamics, Inc. (NASDAQ:ANGO) to report on July, 12. its quarterly earnings Wall Street analysts expect $0.16 EPS, down $0.03 or 15.79 % from last year’s $0.19 same quarter earnings. This translates into $6.00 million profit for ANGO giving the stock a 25.47 P/E. This is assuming the current $0.16 EPS is accurate. AngioDynamics, Inc.’s Wall Street analysts see -15.79 % negative EPS growth, taking into account the $0.19 EPS reproted in the previous quarter, About 2,571 shares traded. AngioDynamics, Inc. (NASDAQ:ANGO) has risen 31.47% since June 20, 2016 and is uptrending. It has outperformed by 14.77% the S&P500.

AngioDynamics, Inc. (NASDAQ:ANGO) Ratings Coverage

Among 7 analysts covering AngioDynamics (NASDAQ:ANGO), 2 have Buy rating, 0 Sell and 5 Hold. Therefore 29% are positive. AngioDynamics had 10 analyst reports since July 24, 2015 according to SRatingsIntel. As per Monday, August 31, the company rating was upgraded by Zacks. Cantor Fitzgerald initiated the stock with “Buy” rating in Friday, November 4 report. The firm earned “Neutral” rating on Wednesday, September 23 by Sidoti. Barclays Capital initiated it with “Equal Weight” rating and $17 target in Wednesday, February 8 report. The firm earned “Neutral” rating on Friday, April 8 by Piper Jaffray. The stock has “Hold” rating by Canaccord Genuity on Wednesday, May 31. The stock of AngioDynamics, Inc. (NASDAQ:ANGO) has “Overweight” rating given on Friday, July 24 by KeyBanc Capital Markets. Canaccord Genuity downgraded the shares of ANGO in report on Tuesday, April 5 to “Hold” rating. The firm has “Buy” rating given on Friday, January 8 by Canaccord Genuity. The stock of AngioDynamics, Inc. (NASDAQ:ANGO) earned “Mkt Perform” rating by Raymond James on Tuesday, November 10.

AngioDynamics, Inc. designs, manufactures and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The company has market cap of $611.30 million. The Company’s devices are used in minimally invasive, image-guided procedures. It currently has negative earnings. The Firm offers products within three product groupings: Peripheral Vascular, Vascular Access and Oncology/Surgery.

More important recent AngioDynamics, Inc. (NASDAQ:ANGO) news were published by: which released: “AngioDynamics Announces FDA Clearance for The Solero Microwave Tissue Ablation …” on June 07, 2017, also published article titled: “AngioDynamics to Present at the 2017 UBS Global Healthcare Conference”, published: “AngioDynamics Lawsuit Alleges CR Bard is Violating Antitrust Laws, Harming …” on May 31, 2017. More interesting news about AngioDynamics, Inc. (NASDAQ:ANGO) was released by: and their article: “Bard Hit With Antitrust Suit Over Alleged Catheter Tying” with publication date: June 01, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.